ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver an oral presentation reviewing the scientific rationale for targeting the Fas receptor and the design of a Phase 1b study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with progressing open-angle glaucoma (OAG) at the upcoming XXVth Biennial Meeting of the International Society for Eye Research (ISER).